Literature DB >> 15902827

Coronary thrombosis related to use of Xenadrine RFA.

Rajesh Sachdeva1, Satish Sivasankaran, Robert F Fishman, Stuart W Zarich, Craig A McPherson.   

Abstract

Recently, ephedra was removed from the U.S. marketplace due to a heightened concern that dietary supplements containing ephedra may present "an unreasonable risk of illness or injury." This is the 1st time the U.S. Food and Drug Administration has banned an herbal supplement, and the ban sheds light on the potential harm of nutritional supplements that are used for weight loss or as a boost to athletic performance. We report the case of a body builder who used Xenadrine RFA, an ephedra-containing supplement, at recommended doses for nearly a year; he then experienced an acute myocardial infarction, which was documented to be secondary to thrombosis in situ. We ruled out other possible causes of myocardial infarction, as well a hypercoagulable state. There was no evidence of illicit drug use. Our report serves as a poignant reminder of the potential dangers of herbal supplementation, especially when used to heighten athletic performance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15902827      PMCID: PMC555829     

Source DB:  PubMed          Journal:  Tex Heart Inst J        ISSN: 0730-2347


  16 in total

1.  Content versus label claims in ephedra-containing dietary supplements.

Authors:  B J Gurley; S F Gardner; M A Hubbard
Journal:  Am J Health Syst Pharm       Date:  2000-05-15       Impact factor: 2.637

2.  "All but death, can be adjusted". Ma Huang (ephedrine) adversities.

Authors:  R B Mack
Journal:  N C Med J       Date:  1997 Jan-Feb

3.  Sudden death of a healthy college student related to ephedrine toxicity from a ma huang-containing drink.

Authors:  T C Theoharides
Journal:  J Clin Psychopharmacol       Date:  1997-10       Impact factor: 3.153

4.  Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine.

Authors:  David Samenuk; Mark S Link; Munther K Homoud; Robert Contreras; Theoharis C Theoharides; Paul J Wang; N A Mark Estes; Theoharis C Theohardes
Journal:  Mayo Clin Proc       Date:  2002-01       Impact factor: 7.616

5.  Hypersensitivity myocarditis associated with ephedra use.

Authors:  S M Zaacks; L Klein; C D Tan; E R Rodriguez; J B Leikin
Journal:  J Toxicol Clin Toxicol       Date:  1999

6.  Ephedrine pharmacokinetics after the ingestion of nutritional supplements containing Ephedra sinica (ma huang).

Authors:  B J Gurley; S F Gardner; L M White; P L Wang
Journal:  Ther Drug Monit       Date:  1998-08       Impact factor: 3.681

7.  Stroke associated with ephedrine use.

Authors:  A Bruno; K B Nolte; J Chapin
Journal:  Neurology       Date:  1993-07       Impact factor: 9.910

8.  Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.

Authors:  C A Haller; N L Benowitz
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 176.079

9.  Ischaemic stroke in a sportsman who consumed MaHuang extract and creatine monohydrate for body building.

Authors:  K Vahedi; V Domigo; P Amarenco; M G Bousser
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-01       Impact factor: 13.654

10.  Cytotoxicity assessment of Ma-huang (Ephedra) under different conditions of preparation.

Authors:  M K Lee; B W Cheng; C T Che; D P Hsieh
Journal:  Toxicol Sci       Date:  2000-08       Impact factor: 4.109

View more
  2 in total

1.  Dilated cardiomyopathy following use of xenadrine EFX.

Authors:  Graziano Riccioni; Giuseppe Speziale; Luca Scotti; Valentina Bucciarelli; Silvia Cappetti; Giuseppe Nasso; Sabina Gallina; Tonino Bucciarelli
Journal:  Int J Immunopathol Pharmacol       Date:  2015-12-17       Impact factor: 3.219

Review 2.  Drug-induced thrombosis: an update.

Authors:  Yuval Ramot; Abraham Nyska; Galia Spectre
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.